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i.org/1ciated with major adverse cardiac event (MACE) rates as high as 30%. In the ORBIT II
(Evaluate the Safety and Efﬁcacy of OAS in Treating Severely Calciﬁed Coronary Lesions)
trial, treatment of de novo severely calciﬁed lesions with the Diamondback 360 Coronary
Orbital Atherectomy System (OAS) resulted in low rates of procedural and 30-day adverse
ischemic events. The long-term results from this trial have not been reported. We sought to
determine the 1-year outcomes after orbital atherectomy of severely calciﬁed coronary
lesions. ORBIT II was a single-arm trial enrolling 443 subjects at 49 US sites with severely
calciﬁed lesions usually excluded from randomized trials. OAS utilizes a centrifugal differ-
ential sanding mechanism of action for plaque modiﬁcation prior to stent implantation. After
OAS drug-eluting stents were implanted in 88.2% of the patients. The primary safety end
point was 30-day MACE, the composite of cardiac death, myocardial infarction, or target
vessel revascularization [TVR]. The present analysis reports the 1-year follow-up results
from ORBIT II. One-year data were available in 433 of 443 patients (97.7%), with median
follow-up time of 16.7 months. The 1-year MACE rate was 16.4%, including cardiac death
(3.0%), myocardial infarction (9.7%), and target vessel revascularization (5.9%). The 1-year
target lesion revascularization rate was 4.7%, and stent thrombosis occurred in 1 patient
(0.2%). Independent predictors of 1-year MACE and target vessel revascularization were
diameter stenosis at baseline and the use of bare-metal stents. In patients with severely
calciﬁed lesions who underwent percutaneous coronary intervention, the use of OAS was
associated with low rates of 1-year adverse ischemic events compared with historical controls.
This ﬁnding has important clinical implications for the selection of optimum treatment
strategies for patients with severely calciﬁed lesions.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2015;115:1685e1690)Despite advances in technology, percutaneous coronary
intervention (PCI) of severely calciﬁed coronary lesions re-
mains a challenge. Contemporary studies have shown that the
presence of moderate or severe coronary calciﬁcation at the
target lesion is associated with a substantial increase in death,
myocardial infarction (MI), stent thrombosis, and need for
revascularization.1e6 Coronary calciﬁcation is frequent, with
about 1/3 of the lesions treated by PCI presenting with
a substantial amount of calciﬁcation angiographically.1 Cur-
rent therapeutic options to manage calciﬁed lesions (e.g.,iversity Medical Center, New York, New York; bCar-
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0.1016/j.amjcard.2015.03.009cutting/scoring balloons and rotational atherectomy) are
associated with a high rate of restenosis and stent failure at
long-term follow-up.5 Recently, the ORBIT II (Evaluate the
Safety and Efﬁcacy of OAS in Treating Severely Calciﬁed
Coronary Lesions) trial demonstrated favorable procedural
and 30-day outcomes with the Diamondback 360 Coronary
Orbital Atherectomy System (OAS) (Cardiovascular Sys-
tems, Inc., St. Paul, Minnesota) in the treatment of severely
calciﬁed lesions, resulting in its Food and Drug Administra-
tion (FDA) approval.7 Whether the beneﬁcial effects of this
device seen at 30 days translate into favorable 1-year out-
comes is not known.We report the prespeciﬁed analysis of the
1-year outcomes from the ORBIT II pivotal trial.Methods
The design and initial results of ORBIT II have been
published previously.7 In brief, ORBIT II was a prospec-
tive, multicenter, nonblinded, single-arm clinical trial that
enrolled patients with de novo severely calciﬁed coronary
lesions who underwent PCI. Key study inclusion criteria
included: (1) target vessel reference diameter 2.5 andwww.ajconline.org
Table 1
Baseline, angiographic, and procedural characteristics
Variable N ¼ 443
Age (years) 71.4  9.9
Men 286/443 (64.6%)
Smoker (current or former) 293/443 (66.1%)
History of diabetes mellitus 160/443 (36.1%)
History of dyslipidemia 407/443 (91.9%)
History of hypertension 406/443 (91.6%)
Estimated glomerular ﬁltration
rate (mL/min/1.73 m2)
75.8  26.2
Prior stroke/transient ischemic attack 39/443 (8.8%)
Prior myocardial infarction 99/443 (22.3%)
Prior coronary artery bypass graft surgery 65/443 (14.7%)
Target coronary artery
Left anterior descending 227/440 (51.6%)
Left circumﬂex 64/440 (14.5%)
Left main 10/440 (2.3%)
Right 132/440 (30.0%)
Ramus 7/440 (1.6%)
Mean lesion length (mm) 18.9  9.0
Mean diameter stenosis (%) 84.4  9.0
Mean reference vessel diameter (mm) 3.1  0.4
American College of Cardiology/American Heart Association lesion type
Type A 0/440 (0.0%)
Type B1 114/440 (25.9%)
Type B2 197/440 (44.8%)
Type C 129/440 (29.3%)
Subjects with stent implanted 432/440 (98.2%)
Stents implanted per patient 1.3  0.6
Types of stents implanted
Bare metal stent 64/542 (11.8%)
Drug-eluting stent 478/542 (88.2%)
First-generation drug-eluting stent 94/478 (19.7%)
Second-generation drug-eluting stent 384/478 (80.3%)
Total procedure time (min)* 52.5  29.6
Total ﬂuoroscopy time (min) 18.2  12.3
Total volume of contrast used (mL) 173.9  86.4
Orbital atherectomy system device used (size in mm)
Pneumatic, 1.25 320/457 (70.0%)
Pneumatic, 1.50 33/457 (7.2%)
Pneumatic, 1.75 2/457 (0.4%)
Pneumatic, 2.00 2/457 (0.4%)
Electric, 1.25 98/457 (21.4%)
Electric, 1.50 2/457 (0.4%)
Orbital atherectomy system
device speed(s) used (rpm)
Low only (80,000) 93/432 (21.5%)
Low and high (80,000/120,000) 317/432 (73.4%)
High only (120,000) 22/432 (5.1%)
Total orbital atherectomy system
device run time (seconds)
66.8  45.6
Individual orbital atherectomy
system run time (seconds)
19.5  5.7
Values are n/N (%), mean  standard deviation.
* Total procedure time deﬁned as the time from when the ﬁrst guide
catheter was placed in the access site to the time the last guide catheter was
removed from the access site.
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50% and <70% with evidence of clinical ischemia
through positive stress test, fractional ﬂow reserve value
0.8, or intravascular ultrasound (IVUS) minimum lumen
area 4.0 mm2; (2) target lesion length 40 mm; and (3)
imaging evidence of severe calcium at the lesion site based
on the angiographic presence of radio-opacities noted
without cardiac motion before contrast injection involving
both sides of the arterial wall in at least 1 location, total
length of calcium of 15 mm and extending partially into
the target lesion, or presence of 270 of calcium at 1
cross-section through IVUS. Patients were excluded if (1)
the target vessel had a stent from a previous PCI unless the
stent was on a different branch than the target lesion and
was implanted >30 days before with no >30% in-stent
restenosis; (2) recent MI (deﬁned as creatine kinase-MB
[CK-MB] >1 upper limit of laboratory normal [ULN]
within 30 days of the index procedure); and (3) evidence of
current left ventricular ejection fraction 25%. The
ORBIT II trial conformed to ethical guidelines of the
Declaration of Helsinki, and study participants provided
informed consent.
The coronaryOAS uses a diamond-coated eccentric crown
that, while rotating over an atherectomy guide wire, expands
laterally through centrifugal force (up to a maximum orbit
diameter for a given rotational speed) resulting in a differ-
ential sanding of coronary calciﬁcation. Two OAS conﬁgu-
rations were used in the ORBIT II trial, pneumatic OAS and
electric OAS, with crown diameter ranging from 1.25 up to
2.00 mm. Detailed description of OAS mechanism of action
can be found elsewhere.8,9 The use of other adjunctive de-
vices, such as thrombectomy, embolic protection devices,
brachytherapy, or cutting balloons, was not allowed. Pre- and
postprocedure dual antiplatelet therapy was recommended to
conform to the American Heart Association/American Col-
lege of Cardiology/Society for Cardiovascular Angiography
and Interventions joint guidelines for PCI.10
The primary safety end point of ORBIT II was the rate of
30-day major adverse cardiac events (MACEs) deﬁned as
the composite of cardiac death, MI, and target vessel
revascularization (TVR). MI was deﬁned as CK-MB >3x
ULN with or without new pathologic Q waves. Rate of stent
thrombosis was reported and deﬁned according to the Ac-
ademic Research Consortium deﬁnition.11 All adverse
events were adjudicated by an independent clinical events
committee. All patients were followed clinically during the
index hospitalization, at 30 days and at 1 year.
Continuous variables are summarized as mean  SD.
Survival curves for time-to-event variables were constructed
on the basis of all available follow-up data using Kaplan-
Meier methods. Multivariable Cox proportional hazards
regression was performed to identify independent predictors
of 1-year MACE and target vessel revascularization (TVR)
(2-sided a ¼ 0.05 for signiﬁcance). The multivariable model
was built with candidate variables being selected if of
clinical interest and/or satisfying the criterion of p <0.2 in
the univariate analysis. Variables included in the ﬁnal were
carefully selected to avoid overﬁtting and included for
MACE: age, previous coronary artery bypass graft surgery,
estimated glomerular ﬁltration rate, reference vesseldiameter, lesion length, diameter stenosis, and use of bare-
metal stents (BMS) versus drug-eluting stents (DES), and
for TVR: reference vessel diameter, diameter stenosis, and
use of BMS versus DES. All statistical analyses were
Figure 1. Time-to-event curves through 1 year. Cumulative event rates through 1 year in patients enrolled in the ORBIT II trial—(A) MACE, (B) cardiac death,
and (C) TVR.
Table 2
Clinical outcomes through time
Variable In-Hospital 30-Day 1-Year
Major adverse cardiac events 43 (9.8) 46 (10.4) 72 (16.4)
Major adverse cardiac events (using myocardial infarction ¼ creatine kinase-MB 10 upper limit of normal) 11 (2.5) 14 (3.2) 43 (9.9)
Death 2 (0.5) 2 (0.5) 19 (4.4)
Cardiac death 1 (0.2) 1 (0.2) 13 (3.0)
Myocardial infarction (creatine kinase-MB 3 upper limit of normal) 41 (9.3) 43 (9.7) 43 (9.7)
NoneQ-wave myocardial infarction 38 (8.6) 39 (8.8) 39 (8.8)
Q-wave myocardial infarction 3 (0.7) 4 (0.9) 4 (0.9)
Myocardial infarction (creatine kinase-MB 10 upper limit of normal) 9 (2.1) 9 (2.0) 9 (2.0)
Target vessel revascularization 3 (0.7) 6 (1.4) 25 (5.9)
Target lesion revascularization 0 (0.0) 3 (0.7) 20 (4.7)
Target vessel revascularization non-target lesion revascularization 3 (0.7) 3 (0.7) 8 (1.9)
Academic Research Consortium deﬁnite/probable stent thrombosis 1 (0.2) 1 (0.2) 1 (0.2)
Kaplan-Meier rate estimates; data presented as n (%). In-hospital rates are based on binomial proportions, out of the 440 treated subjects.
Table 3
One-year clinical events according to stent type
Variable Bare Metal
Stent
(n¼43)
Drug-eluting
Stent
(n¼389)
p Value
Major adverse cardiac events 10 (24.3%) 56 (14.5%) 0.047
Target vessel revascularization 6 (15.1%) 18 (4.7%) 0.01
Target lesion revascularization 6 (15.3%) 13 (3.4%) 0.002
Target vessel revascularization
non-target lesion revascularization
2 (5.0%) 6 (1.6%) 0.15
Kaplan-Meier rate estimates. Data presented as n (%). P-value from Cox
Proportional hazards model.
Coronary Artery Disease/ORBIT II Trial 1-Year Results 1687performed using SAS, version 9.3 (SAS Institute, Cary,
North Carolina).
The ORBIT II trial was funded by Cardiovascular Sys-
tems, Inc., and was designed collaboratively by the steering
committee and the sponsor. The authors had unrestricted
access to the study data, drafted the manuscript, made the
decision to submit for publication, and guarantee the
integrity and accuracy of its content.
Results
From May 25, 2010, to November 26, 2012, 443
consecutive patients with severely calciﬁed coronary lesions
Table 4
Analysis of independent predictors of 1-year adverse events
Variable Major Adverse Cardiac Events Target Vessel Revascularization
Unadjusted
Hazard Ratio
(95%
Conﬁdence
Interval)
p Value Adjusted
Hazard Ratio
(95%
Conﬁdence
Interval)
p Value Unadjusted Hazard
Ratio (95%
Conﬁdence
Interval)
p Value Adjusted Hazard
Ratio (95%
Conﬁdence
Interval)
p Value
Age (per 10 years) 1.02 (0.81, 1.30) 0.84 0.87 (0.67, 1.12) 0.27 0.99 (0.95, 1.02) 0.45
Diabetes mellitus 1.00 (0.62, 1.61) 0.99 1.01 (0.45, 2.29) 0.98
Smoker* 0.79 (0.49, 1.27) 0.32 0.64 (0.29, 1.41) 0.27
Prior myocardial infarction 1.07 (0.62, 1.84) 0.81 1.10 (0.44, 2.75) 0.84
Prior coronary artery bypass grafting 1,57 (0.89, 2.78) 0.12 1.21 (0.64, 2.29) 0.56 1.46 (0.55, 3.88) 0.45
Estimated glomerular ﬁltration rate
(mL/min/1.73 m2) (per 10)
0.94 (0.86, 1.03) 0.21 0.95 (0.86, 1.04) 0.26 1.09 (0.95, 1.25) 0.20
Left ventricular ejection fraction (per 10%) 0.94 (0.74, 1.19) 0.61 1.10 (0.72, 1.69) 0.65
Reference vessel diameter (mm) baseline 0.64 (0.35, 1.16) 0.14 0.74 (0.40, 1.39) 0.35 0.47 (0.17, 1.33) 0.16 0.37 (0.12, 1.14) 0.08
Narrowing length (mm) 1.02 (1.00, 1.05) 0.09 1.02 (0.99, 1.04) 0.26 1.01 (0.97, 1.06) 0.56
Diameter stenosis (%) 1.03 (1.00, 1.05) 0.052 1.03 (1.00, 1.06) 0.04 1.05 (1.00, 1.10) 0.04 1.06 (1.00, 1.11) 0.04
Bare metal stent vs drug-eluting stent 1.93 (1.01, 3.68) 0.047 2.33 (1.17, 4.65) 0.02 3.38 (1.34, 8.52) 0.01 4.38 (1.69, 11.35) 0.002
1.25 mm vs >1.25 mm crown 1.24 (0.50, 3.08) 0.64 1.02 (0.24, 4.34) 0.98
* Current/former smoker versus never smoked.
1688 The American Journal of Cardiology (www.ajconline.org)from 49 US sites were enrolled in the ORBIT II trial. Among
them, 432 (97.5%) were actually treated with OAS before
stent placement, and 1-year data were available in 433
patients (97.7%) (median follow-up time of 16.7 months).
Baseline, angiographic, and procedural characteristics of the
study population are listed in Table 1. DES were implanted in
most of the lesions treated (88.2% of stents).
At 1 year, the primary composite end point of MACE
occurred in 16.4% of patients, with cardiac death occurring
in 3.0%, MI in 9.7%, and TVR in 5.9% of patients
(Figure 1, Table 2). The target lesion revascularization
(TLR) rate was 4.7%, and only 1 (0.2%) stent thrombosis
occurred within 1 year (Table 2). When using the SCAI
deﬁnition of periprocedural MI (CK-MB 10 ULN
without new Q waves or 5 ULN with new Q waves),12
the 1-year MI and MACE rates were 2.0% and 9.9%,
respectively. Table 3 lists the rates of 1-year adverse clinical
events stratiﬁed by stent type. Use of BMS was associated
with a signiﬁcantly higher rate of MACE, TVR, and TLR at
1 year.
Independent predictors of 1-year MACE and TVR are
summarized in Table 4. After multivariable analysis,
diameter stenosis and the use of BMS emerged as inde-
pendent predictors of MACE and TVR.
Discussion
The present study describes the long-term impact of
treatment of severely calciﬁed lesions using the novel and
recently FDA-approved OAS. The main ﬁndings of the
present study extend the favorable procedural and 30-day
results previously reported7 and demonstrate a relatively
low rate of 1-year adverse ischemic events after treatment of
this complex and high-risk cohort with OAS.
PCI of calciﬁed lesions have been shown to be associated
with a worse prognoses compared with lesions with no
calciﬁcation.1e3,5,6 Coronary calciﬁcation often leads todifﬁculty in delivering coronary devices, may damage the
drug polymer and stent platform,13 and limit full stent
expansion, resulting in suboptimal procedural results and an
increased risk of subsequent ischemic adverse events.
Appropriate lesion preparation remains crucial to ensure
optimal angiographic and clinical outcomes. However,
despite improving procedural success and acute gain, the
Rotational Atherectomy Prior to Taxus Stent Treatment for
Complex Native Coronary Artery Disease (ROTAXUS) trial
failed to demonstrate any clinical beneﬁt of rotational athe-
rectomy compared with standard balloon predilation for
preparation of calciﬁed lesions before DES implantation in
regard to 9-month TVR (16.7% vs 18.3%, p ¼ 0.73), TLR
(11.7% vs 12.5%, p ¼ 0.85), and MACE rates (deﬁned as a
composite of death, MI, and TVR; 24.2% vs 28.3%, p ¼
0.46).14 In contrast, the results with OAS in the present study
are encouraging, with lower rates of TVR (5.9%), TLR
(4.7%), and cumulative MACE (16.7%) at 1 year compared
with historical controls, despite using a more stringent deﬁ-
nition of severe coronary calciﬁcation as an enrolling crite-
rion. Indeed, >90% of the treated lesions in the ORBIT II
trial were considered severely calciﬁed compared with
w50% of the lesions enrolled in ROTAXUS.14 Similarly,
our results compared favorably with the recently published
large pooled analysis from the Acute Catheterization and
Urgent Intervention Triage Strategy and Harmonizing Out-
comes With Revascularization and Stents in Acute Myocar-
dial Infarction trials, showing TLR and MACE rates in
patients with severe coronary calciﬁcation who underwent
PCI being 8.7% and 19.9%, respectively.1 That being said,
ORBIT II was a single-arm trial with no direct comparator,
and conclusions from indirect comparisons with different
studies (including different patient populations, different
stent types, etc.) should be considered hypothesis generating.
Given the angiographic complexity and high-risk proﬁle
of the ORBIT II population, the 1-year stent thrombosis rate
is surprisingly low and compares favorably with previous
Coronary Artery Disease/ORBIT II Trial 1-Year Results 1689studies.15e17 Indeed, only 1 case (0.2%) of stent thrombosis
occurred (at day 0, postprocedure). This ﬁnding is notable
and may represent one of the most beneﬁcial effects of OAS
as an optimal tool in lesion preparation for severely calciﬁed
lesions. Angiographic lesion complexity and calciﬁcation
have been identiﬁed as independent predictors of stent
thrombosis,1,18e20 with stent underexpansion being the most
likely causal common denominator.21e23 Although our
ﬁndings are encouraging given the complexity of the lesions
treated in ORBIT II, the relatively small number of patients
enrolled in our study and the lack of a control arm preclude
deﬁnitive conclusions regarding the utility of OAS to prevent
stent thrombosis.
Several reasons could underlie the favorable long-term
results seen in the present study. OAS uses a principle of
off-axis centrifugal force, with the orbital motion diameter
being proportional to the applied speed. This orbital move-
ment results in sanding of the entire calciﬁed wall and might
allow for greater blood ﬂow (nonocclusive) with less heat
generation and thermal injury during the procedure compared
with a potentially more aggressive and occlusive atherec-
tomy approach.24,25 Additional imaging and mechanistic
studies are required to determine the extent to which the
unique mechanism of OAS contributes to the favorable
outcomes observed in the present study.
Approximately 12% of the ORBIT II population under-
went PCI of the target lesion with BMS during the index
procedure. Not surprisingly, adverse ischemic event were
higher in patients with BMS compared with DES, and the
use of BMS was identiﬁed as an independent predictor of
MACE and TVR. Reported previously,26 this ﬁnding re-
iterates the dismal outcomes of BMS compared with DES
when used in highly complex (i.e., heavily calciﬁed) lesions.
This ﬁnding also underlines the even more favorable results
of lesion preparation using OAS, especially if only DES
(speciﬁcally second generation) were used.27
ORBIT II has important strengths. It is the ﬁrst and
largest prospective, multicenter trial including only patients
with severe coronary calciﬁcation using strict angiographic
enrolling criteria in the contemporary era of DES and
potent antithrombotic agents. Indeed, ORBIT II enrolled
patients typically excluded from standard clinical trials
and still demonstrated outcomes comparable with trials
excluding such patients. An independent angiographic core
laboratory and independent clinical events committee
reviewed and adjudicated all angiograms and adverse
events. However, some limitations should be acknowl-
edged. First, ORBIT II was a single-arm trial, with no
control group. Therefore, extrapolation of the superiority
of the OAS device compared with the standard strategy for
treatment of severely calciﬁed lesions could not be done.
That being said, given that no device was FDA approved
for treatment of calciﬁed lesions at the time of conception
of the trial, design of a head-to-head trial was deemed not
necessary by the FDA. Second, adjunctive intracoronary
imaging such as IVUS or optical coherence tomography
was not mandated per protocol. Additional data from these
imaging techniques would have been highly informative
and could have provided insights on the therapeutic
mechanisms and effects of OAS.28,29 Third, 49 sites ran-
domized 443 patients, with a mean of w8 patients enrolledper site. Because the OAS device was a novel therapeutic
tool and most of the investigators had no previous expe-
rience with this device, learning curve issues must be
considered, and improved outcomes may be expected with
increased operator experience.Acknowledgment: The authors thank the ORBIT II in-
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